Clinical Trials Logo

Clinical Trial Summary

Primary study objective: To verify the efficacy of HBM9161 subcutaneous injection in Chinese patients with gMG


Clinical Trial Description

This is a multicenter, randomized, double-blind, placebo-controlled, seamless and group sequential phase 2/3 study to evaluate the efficacy and safety of HBM9161 (HL161) subcutaneous injection in patients with generalized myasthenia gravis Phase 3 study design: A total of 120 subjects with positive AChR-Ab or MuSK-Ab and up to 24 subjects with negative AChR-Ab and MuSK-Ab are planned for this phase (The randomization will end after approximately 120 subjects with positive serum AchR-Ab or MUSK-Ab are enrolled) and randomized into 2 treatment regimens in a 1:1 ratio. Arm 1 will receive HBM9161 680 mg; Arm 2 will receive placebo. Whether or not AChR-Ab or MuSK-Ab is positive, and whether or not concomitant steroids are used will be randomization stratification factors. First, eligible subjects will be screened into the double-blind treatment phase and blindly assigned to receive either HBM9161 680 mg or placebo for the first treatment period, administered once weekly (QW) for 6 doses. Subjects who complete the first treatment period will start the administration of the second treatment period if they meet the dosing criteria for the second treatment period at Week 9. The second treatment period will be administered once weekly (QW) for a total of 6 doses in the first treatment period, followed by an observation period (4 weeks) and a follow-up period. Subjects will be dosed for up to two treatment cycles during the study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05039190
Study type Interventional
Source Harbour BioMed (Guangzhou) Co. Ltd.
Contact Chongbo Zhao
Phone +86 13701822316
Email [email protected]
Status Not yet recruiting
Phase Phase 3
Start date September 10, 2021
Completion date October 30, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT01727193 - The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy Phase 3
Completed NCT00285350 - Mycophenolate Mofetil in Myasthenia Gravis Phase 3
Not yet recruiting NCT04965987 - Oxaloacetate in Myasthenia Gravis Phase 1
Recruiting NCT02774239 - A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG) Phase 3
Completed NCT02066519 - Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis N/A
Terminated NCT02102594 - Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB) Phase 2
Suspended NCT02118805 - Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders
Terminated NCT01828294 - Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis Phase 1
Terminated NCT00727194 - Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis Phase 2
Completed NCT04590716 - Help Build an A.I. Model to Predict Myasthenia Gravis Symptom Patterns and Flares
Recruiting NCT04837625 - A Multicenter Prospective Registration Study of Myasthenic Crisis in China
Not yet recruiting NCT04535843 - Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China
Not yet recruiting NCT01469858 - Perception and Multisensory Integration in Neurological Patients Using fMRI N/A
Completed NCT03205306 - Myasthenia Gravis and Psyche
Recruiting NCT04695379 - Follow-up of a Cohort of Patients With Myasthenic Syndrome and COVID-19 Infection
Completed NCT03863080 - A Study of RVT-1401 in Myasthenia Gravis (MG) Patients Phase 2
Completed NCT02100969 - Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis Phase 2
Completed NCT02110706 - BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis Phase 2
Active, not recruiting NCT01105923 - Study of an Intervention to Improve Problem List Accuracy and Use N/A
Active, not recruiting NCT00997412 - Trial of Mycophenolic Acid Versus Azathioprine in the Treatment of Corticosteroid-refractory Myasthenia Gravis N/A